Price (delayed)
$1.38
Market cap
$2.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$87.38
Enterprise value
-$2.07M
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, ...
Highlights
APVO's EPS has surged by 96% year-on-year and by 87% since the previous quarter
The company's debt fell by 14% YoY and by 4.2% QoQ
Aptevo Therapeutics's equity has shrunk by 61% YoY but it has increased by 8% QoQ
The quick ratio has contracted by 40% YoY but it has grown by 6% from the previous quarter
APVO's net income is down by 39% YoY
Key stats
What are the main financial stats of APVO
MarketValuationsEarnings
Shares outstanding
1.46M
Market cap
$2.01M
Enterprise value
-$2.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$24.6M
Net income
-$24.13M
EBIT
-$24.13M
EBITDA
-$23.78M
Free cash flow
-$23.79M
Per shareBalance sheetLiquidity
EPS
-$87.38
EPS diluted
-$87.38
Free cash flow per share
-$86.13
Book value per share
$9.5
Revenue per share
$0
TBVPS
$56.46
Total assets
$15.59M
Total liabilities
$10.84M
Debt
$4.63M
Equity
$4.76M
Working capital
$4.45M
Debt to equity
0.97
Current ratio
1.72
Quick ratio
1.4
Net debt/EBITDA
0.17
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-152.5%
Return on equity
-488.9%
Return on invested capital
-395.6%
Return on capital employed
-257.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APVO stock price
How has the Aptevo Therapeutics stock price performed over time
Intraday
38.26%
1 week
-10.39%
1 month
-63.87%
1 year
-99.06%
YTD
-67.98%
QTD
18.97%
Financial performance
How have Aptevo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.6M
Net income
-$24.13M
Gross margin
N/A
Net margin
N/A
APVO financials
APVO's net income is down by 39% YoY
The company's operating income rose by 15% YoY
Growth
What is Aptevo Therapeutics's growth rate over time
APVO growth chart
Valuation
What is Aptevo Therapeutics stock price valuation
P/E
N/A
P/B
0.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
APVO's EPS has surged by 96% year-on-year and by 87% since the previous quarter
Price to book (P/B)
APVO's P/B is 97% below its 5-year quarterly average of 5.1 and 63% below its last 4 quarters average of 0.4
Aptevo Therapeutics's equity has shrunk by 61% YoY but it has increased by 8% QoQ
Price to sales (P/S)
Efficiency
How efficient is Aptevo Therapeutics business performance
Aptevo Therapeutics's ROA has plunged by 154% YoY and by 17% from the previous quarter
The company's return on invested capital has shrunk by 67% YoY and by 5% QoQ
The return on equity has declined by 40% since the previous quarter
Dividends
What is APVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APVO.
Financial health
How did Aptevo Therapeutics financials performed over time
Assets vs liabilities
APVO's total assets is 44% higher than its total liabilities
The quick ratio has contracted by 40% YoY but it has grown by 6% from the previous quarter
APVO's total assets is down by 37% YoY but it is up by 2.9% QoQ
Debt vs equity
The company's debt is 2.6% lower than its equity
The debt to equity has soared by 120% YoY but it fell by 11% QoQ
Aptevo Therapeutics's equity has shrunk by 61% YoY but it has increased by 8% QoQ
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.